NEPHROPROTECTIVE THERAPY OF HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: IS THERE A PLACE FOR THE THIRD GENERATION OF β-ADRENORECEPTOR BLOCKERS AND I1-IMIDAZOLINE RECEPTOR AGONISTS?

chronic kidney disease, sympathetic hyperactivation, renal sclerotic damage, β-adrenoreceptor blockers, agonists of I1-imidazoline receptor

1. Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 1206-1252

2. Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-1053

3. Комитет экспертов ВНОК. Профилактика, диагностика и лечение артериальной гипертонии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 [Приложение]: 3-19

4. Ruggenenti P, Perna A, Loziga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2): multicentre, randomized controlled trial. Lancet 2005; 365 (9463): 939-946

5. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13-21

6. Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 1936-1939.

7. Eppel GA, Malpas SC, Denton KM, Evans RG. Neural control of renal medullary perfusion. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 387-396

8. Barajas L, Powers K, Wang P. Innervation of renal cortical tubules: a quantitative study. Am J Physiol 1984; 247 (1): F30-F60

9. Cohen HT, Takemoto F, Satoh T, Katz AI. Renal adrenergic receptors: localization of 125 Iprasosin binding sites along the microdissected rat nephron. Can J Physiol Pharmacol 1992; 70 (7): 1016-1020

10. Struyker-Boudier HA, Janssen BJ, Smiths JF. Adrenoreceptors in the kidney: localization and pharmacology. Clin Exp Hypertens 1987; A9, [Suppl 1]: 135-150

11. Wang TT, Chen X, Wu XH et al. Molecular mechanism of action of isoprotorenol on the expression of angiotensinogen gene in opossum kidney proximal tubular cells. Kidney Int 1999; 55 (5): 1713-1723

12. Wolf G, Helmchen U, Stahl RA. Isoprotorenol stimulates tubular DNA replication in mice. Nephrol Dial Transplant 1996; 11 (11): 2288-2292

13. Nakamura A, Imaizumi A, Yanagawa Y et al. Suppression of tumor necrosis factor-alpha by І 2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. Inflam Res2003; 52 (1): 26-31

14. Nakamura A, Imaizumi A, Yanagawa Y. Beta 2-adrenoceptor function in the kidney. Nippon Yakurigaki zasshi 2004; 124 (6): 427-434

15. Tinucci T, Abrahao SB, Santello JL, Mion D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406

16. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol2003; 14 (12): 3239-3244

17. Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. Circulation 2002; 105 (11): 1354-1359

18. Hansberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end stage renal disease. Circulation 2002; 106 (15): 1974-1979

19. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (4): 878-882

20. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99 (3): 540-548

21. Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4 (3): 256-260

22. Miyajima E, Yamada Y, Yoshida Y et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17 (6): 1057-1062

23. Modlinger PC, Wilcox CS, Aslam S. Nitric oxide, oxidative stress and progressive of chronic renal failure. Semin Nephrol 2004; 24 (4): 354-365

24. Campese VM, Shaohua Ye, Huinqin Zhong et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system. Am J Physiol 2004; 287 (2): H795-H703

25. Stegbauer J, Vonend O, Obehauser V et al. Angiotensin II receptor modulation of renal vascular resis itance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res 2005; 28 (1): 20-26

26. Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14 (2): 425-430

27. Eikelis N, Schlaich M, Aggarwal A et al. Interaction between leptin and human sympathetic nervous system. Hypertension 2003; 41 (5): 1072-1079

28. Montanaro MS, Allen AM, Oldfield BJ. Structural and functional evidence supporting a role for leptin in central neural pathways influencing blood pressure in rats. Exp Physio l2005; 90 (5): 689-696

29. Scharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51 (6): 1980-1985

30. Merabet E, Dagogo-Jack S, Coyne DW et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1999; 82 (3): 847-850

31. Кузьмин ОБ, Пугаева МО, Чуб СВ, Ландарь ЛН. Почечные механизмы эссенциальной гипертонии. Нефрология 2005; 9 (2): 23-29

32. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-15

33. Ермаков ЮА, Вишняков НИ, Ковальский ГБ. Хроническая почечная недостаточность у нефрологических больных в Санкт-Петербурге по данным патологоанатомических исследований за 1993–2003 годы. Нефрология 2005; 9 (2): 78-82

34. Denton KM, Shweta A, Flower RL, Anderson WP. Predominant postglomerular vascular resistance response to reflex renal nerve stimulation during Ang II clamp in rabbits. Am J Physio l2004; 287 (4): R780-R786

35. Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19 (2): 342-347

36. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventicia is augmented by injury and mediated by different α1-adrenoceptor subtypes. Circulat Res 2001; 89 (9): 815-822

37. Erami C, Zhang H, Tanoue A et al. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodeling. Am J Physio l2005; 289 (2): H744-H753

38. Johnston RJ, Gordon KL, Suga S et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999; 34 (1): 151-159

39. Nakamura A, Imaizumi A, Yanagawa Y et al. β2-Adrenoceptor activation attenuates endotoxin-induced acute renal failure. J Am Soc Nephrol 2004; 15 (2): 316-325

40. Bohlen L, de Courten M, Weidmann P. Comparative study of the effects of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (9, Pt2): 84S-92S

41. Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963-1974

42. Kalinowski L, Dobrucki LW, Szczeppanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from epithelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747-2752

43. Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Brit J Pharmacol 2001; 134 (5): 977-984

44. Van den Branden C, Gabriels M, Vamecq J et al. Carvedilol protects against glomerulosclerosis in the rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs carvedilol and propranolol. Nephron 1997; 77 (3): 319-324

45. Rodriques-Peres JC, Losada A, Anabitarte A et al. Effects of novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablation rats. J Pharmacol Exp Ther 1997; 283 (1): 336-344

46. Tomita K, Marumo F. Effect of long-term carvedolol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19 [Suppl 1]: S97-S101

47. Zitta S, Stoschitzky K, Zweiker R et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. Nephrol Dial Transplant 2000; 15 (8): 1162-1169

48. Marchi F, Ciriello G. Efficacy of carvedolol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-221

49. Fassbinder W, Quarter O, Waltz A. Treatment with carvedolol is associated with a significant reduction in microalbuminuria: a multicentre randomized study. Int J Clin Pract 1999; 53 (7): 515-522

50. Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46 (6): 1309-1315

51. Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedolol in patients with chronic renal failure. Eur J Pharmacol 1992; 43 (1): 85-88

52. Janssen BJA, Lukoshkova EV, Head GA. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. Am J Physiol 2002; 282 (1): F113-F123

53. Smyth DD, Pirnat D, Forzley B, Penner SB. Apparent absence of direct renal effects of imidazoline receptor agonist. Ann NY Acad Sci 2003; 1009 (1): 288-295

54. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats.J Am Soc Nephrol 2000; 11(8): 1469-1478

55. Vonend O, Apel T, Amann K et al. Modulation of gene expression by moxonidine in rat with chronic renal failure. Nephrol Dial Transplant 2004; 19 (9): 2217-2222

56. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11 (6): 1003-1011

57. Krespi PJ, Makris TK, Hatzizasharias AN et al. Moxonidine effects on microalbuminuria, thrombomodulin and plasminogen activator-I levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-467

58. Демидова ТЮ, Аметов АС, Смагина ЛВ, Виноградова МВ. Органопротективные свойства агониста имидазолиновых рецепторов моксонидина (физиотенза) у больных артериальной гипертонией и сахарным диабетом 2-го типа. Клин фармакол и тер 2004; 13 (5): 21-25

59. Трусов ВВ, Аксенов КВ. Влияние агониста имидазолиновых рецепторов моксонидина на состояние микроциркуляции и функцию почек у больных артериальной гипертонией с сахарным диабетом 2-го типа. Кардиология 2003; 43 (9): 44-48

60. Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7 (1): 57-61

61. Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15 (4): 245-253

62. Singlas E, Ehrhardt JD, Zech P et al. Pharmacokinetics of rilmenidine. Am J Cardiol 1988: 61 (7): 54D-59D